In recent years, several studies have reported a relatively high frequency of polyneuropathy in patients with Parkinson's disease (PD), in particular, in patients receiving levodopa-carbidopa intestinal gel (LCIG) infusion. In spite of the several patients investigated with nerve conduction studies, no study has prospectively explored a possible central nervous system involvement of patients receiving LCIG infusion. We prospectively evaluated eight PD patients receiving LCIG infusion, who underwent neurophysiological evaluations with nerve conduction studies, visual, somatosensory and motor evoked potentials before LCIG infusion, and 1 and 6 months after. At 6 months follow-up, we found significant reduction in sural nerve SNAP amplitude, increase of central sensory conduction time N22-P40, and increases of central motor conduction time recorded from I dorsal interosseous and tibialis anterior. In PD patients with LCIG infusion, we found a subclinical neurophysiological impairment of both peripheral and central nervous system.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10072-017-3029-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson's Disease-Patient Perspective.
Medicina (Kaunas)
December 2024
Department of Neurology, Faculty of Medical Sciences in Katowice, University Clinical Centre Prof K. Gibinski, Medical University of Silesia, 14 Medykow St. 40-752 Katowice, Poland.
The rapid growth of the number of advanced Parkinson's disease (PD) patients has caused a significant increase in the use of device-aided therapies (DATs), including levodopa-carbidopa intestinal gel (LCIG) and continuous subcutaneous apomorphine infusion (CSAI). The objective of this study was to evaluate patients' satisfaction and the factors influencing preferences for CSAI and LCIG. The research focused on individuals diagnosed with advanced PD undergoing DAT at the Neurology Department of the University Hospital in Katowice.
View Article and Find Full Text PDFLong-term effect and reasons for switching and combining device-aided therapies in Parkinson's Disease.
Neurol Neurochir Pol
January 2025
Department of Neurology, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Introduction: In the advanced stages of Parkinson's disease (PD), when standard drug adjustments fail to sufficiently improve patients' quality of life, device-aided therapies (DATs) such as deep brain stimulation (DBS), continuous subcutaneous apomorphine infusion (CSAI), levodopa-carbidopa intestinal gel infusion (LCIG), levodopa-carbidopa-entacapone intestinal gel infusion, or continuous subcutaneous foslevodoa-foscarbidopa infusion are beneficial in the long run. However, sometimes patients need to switch or combine DATs due to either adverse events or loss of efficacy.
Aim Of Study: The aim of this article was to summarise the existing data on the long-term efficacy and adverse events of DATs, and to review the data on the rationale and efficacy for switching or combining DATs in advanced PD.
Direct Initiation of Levodopa-Carbidopa Intestinal Gel Infusion After a Positive Levodopa Challenge Test in Advanced Parkinson's Disease.
Brain Behav
December 2024
Department of Neurology, Helsinki University Hospital, Helsinki, Finland.
Article Synopsis
- LCIG is a treatment for advanced Parkinson's disease, often starting with a nasojejunal tube (NJT) test phase, but some centers have initiated treatment directly with a PEG-J tube.
- A study compared these two methods in 33 advanced PD patients, evaluating treatment discontinuations, adverse events, and hospital stay length.
- Results showed no significant differences in complications or discontinuations between the two methods, but direct initiation with PEG-J reduced hospital stays significantly.
Effects of levodopa/carbidopa intestinal gel infusion on autonomic symptoms in advanced Parkinson's disease: a systematic review.
Clin Auton Res
December 2024
Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Sapienza University of Rome, Via di Grottarossa, 1035, 00189, Rome, Italy.
Article Synopsis
- Autonomic failure significantly affects the quality of life for individuals with advanced Parkinson's disease (PD), prompting the need to evaluate the impact of Levodopa/carbidopa intestinal gel (LCIG) on autonomic dysfunction.
- A systematic review identified 16 studies involving 1361 PD patients, assessing the effects of LCIG on gastrointestinal, urinary, and cardiovascular symptoms over time, with most studies reporting improvements or stability.
- While many patients benefited from LCIG, some experienced worsening autonomic symptoms and there were reports of mild adverse events related to the treatment, highlighting the need for further targeted research in this area.
Risk of fall with device-based advanced treatments in Parkinson's disease: a systematic review and network meta-analysis.
J Neurol Neurosurg Psychiatry
November 2024
Edmond J. Safra Program in Parkinson's Disease and Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada
Background: Deep brain stimulation (DBS) and infusion therapies are effective treatments for the motor complications of Parkinson's disease (PD), but less established is their role in fall prevention. This systematic review and network meta-analysis (NMA) aimed to evaluate the risk of falls associated with advanced therapies in PD.
Methods: Following PRISMA-NMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Network Meta-analyses) guidelines, we searched PubMed, Medline, Embase and CINAHL up to 20 March 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!